Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
NTF3 Biologics Sequence Review Report 2026: Neurotrophin-3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NTF3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRP2 Biologics Sequence Review Report 2026: Neuropilin-2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRP1 Biologics Sequence Review Report 2026: Neuropilin-1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRG4 Biologics Sequence Review Report 2026: Pro-neuregulin-4, membrane-bound isoform Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRG4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRG3 Biologics Sequence Review Report 2026: Pro-neuregulin-3, membrane-bound isoform Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRG3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRG2 Biologics Sequence Review Report 2026: Pro-neuregulin-2, membrane-bound isoform Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRG1 Biologics Sequence Review Report 2026: Pro-neuregulin-1, membrane-bound isoform Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NPY5R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NPY5R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NPSR1 Biologics Sequence Review Report 2026: Neuropeptide S receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NPSR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NPR1 Biologics Sequence Review Report 2026: Atrial natriuretic peptide receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NPR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MUC22 Biologics Sequence Review Report 2026: Mucin-22 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MUC22 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MUC21 Biologics Sequence Review Report 2026: Mucin-21 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MUC21 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.